48.20

0.56% 0.27

Pre-market: 48.30 0.10 +0.21%

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $48.20, with a volume of 748.11K. It is up +0.56% in the last 24 hours and up +6.10% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Previous Close:

$47.93

Open:

$48.24

24h Volume:

748.11K

Relative Volume:

0.71

Market Cap:

$3.87B

Revenue:

$541.74M

Net Income/Loss:

$88.01M

P/E Ratio:

44.37

EPS:

1.0862

Net Cash Flow:

$155.34M

1W Performance:

+7.61%

1M Performance:

+6.10%

6M Performance:

+42.39%

1Y Performance:

+34.00%

1-Day Range:

$0.00

1-Week Range:

$43.90

$48.96

52-Week Range:

$29.45

$60.91

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1053)

Industry

Diagnostics & Research (44)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

755

Twitter

@veracyte

Next Earnings Date

2026-11-04

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, NTRA, A, IQV

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	48.20	3.87B	541.74M	88.01M	155.34M	1.0862
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-15-26	Initiated	Piper Sandler	Overweight
Jun-02-26	Resumed	Wolfe Research	Outperform
Apr-13-26	Initiated	Jefferies	Buy
Dec-02-25	Resumed	Morgan Stanley	Underweight
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

Oct 23, 2026

Veracyte, Inc. Estimates – NASDAQ:VCYT - TradingView

Oct 23, 2026

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer - The Manila Times

Oct 23, 2026

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer - GlobeNewswire Inc.

Oct 23, 2026

Oct 22, 2026

Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT) - Seeking Alpha

Oct 22, 2026

Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com - Investing.com South Africa

Oct 22, 2026